{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:34:10Z","timestamp":1792510450562,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.tjpad.2025.100474","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T01:27:19Z","timestamp":1768354039000},"page":"100474","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer\u2019s disease pathology"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7326-0717","authenticated-orcid":false,"given":"Yonghong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Lagier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Racke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri A.","family":"Fesko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tjpad.2025.100474_bib0001","unstructured":"More than normal aging: Understanding mild cognitive impairment. https:\/\/www.alz.org\/alzheimers-dementia\/what-is-dementia\/related_conditions\/mild-cognitive-impairment. Accessed May 7, 2025."},{"key":"10.1016\/j.tjpad.2025.100474_bib0002","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2015.4668","article-title":"Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis","volume":"313","author":"Jansen","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100474_bib0003","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100474_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer's disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100474_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/alz.14338","article-title":"Updated appropriate use criteria for amyloid and tau PET: a report from the Alzheimer's Association and Society for Nuclear Medicine and Molecular Imaging Workgroup","volume":"21","author":"Rabinovici","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100474_bib0006","first-page":"1","article-title":"Diagnosis of Alzheimer's disease utilizing amyloid and tau as fluid biomarkers","volume":"51","author":"Lee","year":"2019","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.tjpad.2025.100474_bib0007","article-title":"Real-world use of diagnostic tests for mild cognitive impairment, Alzheimer's disease, and other dementias in Medicare fee-for-service beneficiaries","volume":"17","author":"Yan","year":"2025","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.tjpad.2025.100474_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/alz.085540","article-title":"Capacity for Alzheimer\u2019s Disease confirmatory testing in the US - current situation and simulations for future increase","volume":"20","author":"Roth","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100474_bib0009","article-title":"Blood-based biomarkers for Alzheimer's pathology and the diagnostic process for a disease-modifying treatment: projecting the impact on the cost and wait times","volume":"12","author":"Mattke","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.tjpad.2025.100474_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.8392","article-title":"Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment","volume":"5","author":"Hu","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.tjpad.2025.100474_bib0011","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","article-title":"Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests","volume":"30","author":"Barthelemy","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.tjpad.2025.100474_bib0012","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2024.13855","article-title":"Blood biomarkers to detect Alzheimer disease in primary care and secondary care","volume":"332","author":"Palmqvist","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100474_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2024.1364658","article-title":"Clinical utility of plasma Abeta42\/40 ratio by LC-MS\/MS in Alzheimer's disease assessment","volume":"15","author":"Weber","year":"2024","journal-title":"Front Neurol"},{"key":"10.1016\/j.tjpad.2025.100474_bib0014","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1002\/alz.13764","article-title":"Clinical validation of the PrecivityAD2 blood test: a mass spectrometry-based test with algorithm combining %p-tau217 and Abeta42\/40 ratio to identify presence of brain amyloid","volume":"20","author":"Meyer","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100474_bib0015","unstructured":"FDA clears first blood test used in diagnosing Alzheimer\u2019s disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease. Accessed June 14, 2025."},{"key":"10.1016\/j.tjpad.2025.100474_bib0016","doi-asserted-by":"crossref","first-page":"8216","DOI":"10.1002\/alz.14184","article-title":"Recommendations for clinical implementation of blood-based biomarkers for Alzheimer's disease","volume":"20","author":"Mielke","year":"2024","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100474_bib0017","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41582-024-00977-5","article-title":"Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease","volume":"20","author":"Schindler","year":"2024","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.tjpad.2025.100474_bib0018","article-title":"Alzheimer's Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer's disease within specialized care settings","volume":"21","author":"Palmqvist","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100474_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.tjpad.2025.100219","article-title":"Estimation of the value-based price of a blood test for Alzheimer's disease pathology in primary and specialty care in the U.S","author":"Mattke","year":"2025","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100474_bib0020","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1001\/jama.2024.19084","article-title":"Payer coverage considerations for Alzheimer disease blood-based biomarker tests","volume":"332","author":"Deverka","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100474_bib0021","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.tjpad.2025.100474_bib0022","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s13139-021-00690-x","article-title":"A 4-year follow-up of subjects with visually equivocal amyloid positron emission tomography findings from the Alzheimer's Disease Neuroimaging Initiative cohort","volume":"55","author":"Oh","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"key":"10.1016\/j.tjpad.2025.100474_bib0023","unstructured":"Lumipulse G pTau217 \/P-Amyloid 1-42 Plasma Ratio. https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf24\/K242706.pdf. Accessed July 10, 2025."},{"key":"10.1016\/j.tjpad.2025.100474_bib0024","unstructured":"MDSave. https:\/\/www.mdsave.com. Accessed April 18, 2025."},{"key":"10.1016\/j.tjpad.2025.100474_bib0025","unstructured":"First Blood Test to Diagnose Alzheimer\u2019s Cleared by FDA. https:\/\/www.everydayhealth.com\/neurological-disorders\/first-blood-test-to-diagnose-alzheimers-cleared-by-fda, #:\u223c:text=PET%20scans%20and%20spinal%20taps,might%20cost%20%24500%20to%20%241%2C000. Accessed July 15, 2025."},{"key":"10.1016\/j.tjpad.2025.100474_bib0026","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1089\/pop.2023.0309","article-title":"Use of a blood biomarker test improves economic utility in the evaluation of older patients presenting with cognitive impairment","volume":"27","author":"Canestaro","year":"2024","journal-title":"Popul Health Manag"},{"key":"10.1016\/j.tjpad.2025.100474_bib0027","unstructured":"Beta amyloid positron emission tomography in dementia and neurodegenerative disease. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/ncacal-decision-memo.aspx, ?proposed=N&NCAId=308. Accessed June 5, 2025."},{"key":"10.1016\/j.tjpad.2025.100474_bib0028","doi-asserted-by":"crossref","first-page":"662","DOI":"10.7326\/0003-4819-151-9-200911030-00011","article-title":"Much cheaper, almost as good: decrementally cost-effective medical innovation","volume":"151","author":"Nelson","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.tjpad.2025.100474_bib0029","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1186\/s12913-020-05825-y","article-title":"How to assess the value of low-value care","volume":"20","author":"Sacristan","year":"2020","journal-title":"BMC Health V Res"},{"key":"10.1016\/j.tjpad.2025.100474_bib0030","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000035614","article-title":"A review of cost-effectiveness analysis: from theory to clinical practice","volume":"102","author":"Michelly Goncalves Brandao","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.tjpad.2025.100474_bib0031","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJM198106253042602","article-title":"Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis","volume":"304","author":"Hull","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tjpad.2025.100474_bib0032","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1136\/bmj.307.6907.793","article-title":"Cost-effectiveness analysis","volume":"307","author":"Robinson","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.tjpad.2025.100474_bib0033","article-title":"Blood-based biomarker prescreening with different testing combinations and cutoffs: a simulation study examining efficacy and cost-effectiveness in Alzheimer's disease prevention studies","volume":"11","author":"Sato","year":"2025","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100474_bib0034","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00406-022-01439-z","article-title":"Cost-effectiveness of Alzheimer's disease CSF biomarkers and amyloid-PET in early-onset cognitive impairment diagnosis","volume":"273","author":"Contador","year":"2023","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.tjpad.2025.100474_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.103911","article-title":"Cost-effectiveness comparison between blood biomarkers and conventional tests in Alzheimer's disease diagnosis","volume":"29","author":"Noda","year":"2024","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.tjpad.2025.100474_bib0036","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1001\/jama.2019.2000","article-title":"Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia","volume":"321","author":"Rabinovici","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.tjpad.2025.100474_bib0037","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1002\/alz.12846","article-title":"A more precise diagnosis by means of amyloid PET contributes to delayed institutionalization, lower mortality, and reduced care costs in a tertiary memory clinic setting","volume":"19","author":"van Maurik","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.1016\/j.tjpad.2025.100474_bib0038","doi-asserted-by":"crossref","first-page":"928","DOI":"10.14283\/jpad.2024.67","article-title":"Optimising Alzheimer's disease diagnosis and treatment: assessing cost-utility of integrating blood biomarkers in clinical practice for disease-modifying treatment","volume":"11","author":"Aye","year":"2024","journal-title":"J Prev Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100474_bib0039","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/13872877251323231","article-title":"Cost-effectiveness of diagnosing and treating patients with early Alzheimer's disease with anti-amyloid treatment in a clinical setting","volume":"104","author":"Wimo","year":"2025","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.tjpad.2025.100474_bib0040","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1038\/s43587-023-00471-5","article-title":"A two-step workflow based on plasma p-tau217 to screen for amyloid beta positivity with further confirmatory testing only in uncertain cases","volume":"3","author":"Brum","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.tjpad.2025.100474_bib0041","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s43587-023-00403-3","article-title":"Blood biomarkers for Alzheimer's disease in clinical practice and trials","volume":"3","author":"Hansson","year":"2023","journal-title":"Nat Aging"},{"key":"10.1016\/j.tjpad.2025.100474_bib0042","unstructured":"Alzheimer\u2019s Association welcomes FDA clearance of first blood test for use in primary care to rule out Alzheimer\u2019s-related amyloid pathology. https:\/\/www.alz.org\/news\/2025\/fda-clearance-blood-test-primary-care-rule-out-alzheimers-related-amyloid-pathology. Accessed November 21, 2025."},{"key":"10.1016\/j.tjpad.2025.100474_bib0043","doi-asserted-by":"crossref","first-page":"8074","DOI":"10.1002\/alz.14315","article-title":"Head-to-head comparison of leading blood tests for Alzheimer's disease pathology","volume":"20","author":"Schindler","year":"2024","journal-title":"Alzheimers Dement"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725004157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580725004157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:38:06Z","timestamp":1773261486000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580725004157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2274580725004157"],"URL":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100474","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of blood-based biomarker testing in the diagnosis of Alzheimer\u2019s disease pathology","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tjpad.2025.100474","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS on behalf of SERDI Publisher.","name":"copyright","label":"Copyright"}],"article-number":"100474"}}